Warning Letter Record: Nexlife Inc. dba Nexlife (2026-06-08) — False & Misleading Claims/Misbranded (Telehealth)
Letter issued · posted to fda.gov .
Subject as published: False & Misleading Claims/Misbranded (Telehealth)
TL;DR
In short: FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Nexlife Inc. dba Nexlife on 2026-06-08 regarding False & Misleading Claims/Misbranded (Telehealth). The verbatim letter is published on fda.gov.
Argus analysis
Nexlife Inc. dba Nexlife received a Warning Letter from FDA's Center for Drug Evaluation and Research (CDER), dated 2026-06-08, regarding False & Misleading Claims/Misbranded (Telehealth). The letter follows an FDA inspection and is classified by Argus HQ as critical severity, consistent with labeling or misbranding violations under 21 USC 343 (food) or 21 USC 352 (drugs/devices).
The excerpt below does not contain a machine-extractable 21 CFR section number; FDA classifies this matter as labeling, which generally concerns labeling or misbranding violations under 21 USC 343 (food) or 21 USC 352 (drugs/devices). See the verbatim letter linked below for FDA's exact citation language.
FDA Warning Letters carry a 15-business-day response window for the recipient to detail corrective actions. Peer compliance teams in the same product category typically use a letter like this one as an external audit trigger, checking whether their own quality system has documented coverage for the cited sections and whether their CAPA log would withstand the same line of inspection questioning.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Labeling letters cite 21 USC 343 (food), 21 USC 352 (drugs), or 21 USC 352 (devices). Most are resolved by SKU-level copy revision within the 15-business-day response window.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Nexlife Inc. dba Nexlife MARCS-CMS 730096 — June 08, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Nexlife Inc. dba Nexlife 260 Newport Center Dr. Newport Beach , CA 92660 United States hello@nexlife.us Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 8, 2026 WARNING LETTER Reference number: MARCS-CMS 730096 To Nexlife: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. FDA Review Violations were identified and documented during a review of Nexlife’s website, https://nexlife.us, FDA Establishment Identifier (FEI) 3044820290, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. 1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular. More specifically, 1. The compounded semaglutide and tirzepatide products displayed on your website identify “Nexlife” on the pictured label, suggesting Nexlife is the compounder of those drugs when in fact it is not. 2 Accordingly, the…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Labeling / misbranded warning letter?
- Labeling letters cite 21 USC 343 (food), 21 USC 352 (drugs), or 21 USC 352 (devices). Most are resolved by SKU-level copy revision within the 15-business-day response window.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Nexlife Inc. dba Nexlife had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Nexlife Inc. dba Nexlife as of 2026-06-16. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Nexlife Inc. dba Nexlife (2026-06-08) — False & Misleading Claims/Misbranded (Telehealth). Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-nexlife-inc-dba-nexlife-2026-06-08-labeling
"Warning Letter Record: Nexlife Inc. dba Nexlife (2026-06-08) — False & Misleading Claims/Misbranded (Telehealth)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-nexlife-inc-dba-nexlife-2026-06-08-labeling.
Argus HQ Research. "Warning Letter Record: Nexlife Inc. dba Nexlife (2026-06-08) — False & Misleading Claims/Misbranded (Telehealth)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-nexlife-inc-dba-nexlife-2026-06-08-labeling.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_nexlife_inc_dba_nexlife_2026_06_08_labeling_2026,
title = {Warning Letter Record: Nexlife Inc. dba Nexlife (2026-06-08) — False & Misleading Claims/Misbranded (Telehealth)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-nexlife-inc-dba-nexlife-2026-06-08-labeling},
note = {Accessed: July 13, 2026}
}